Critically short telomeres and toxicity of chemotherapy in early breast cancer

Oncotarget

Volumn 8, Issue 13, 2017, Pages 21472-21482

  Quintela Fandino, Miguel ^a   Soberon, Nora ^a   Lluch, Ana ^b   Manso, Luis ^c   Calvo, Isabel ^d   Cortes, Javier ^e,f   Moreno Antón, Fernando ^g   Gil Gil, Miguel ^h   Martinez Jánez, Noelia ^f   Gonzalez Martin, Antonio ⁱ   Adrover, Encarna ^j   de Andres, Raquel ^k   Viñas, Gemma ^h   Llombart Cussac, Antonio ^l   Alba, Emilio ^m   Mouron, Silvana ^a   Guerra, Juan ⁿ   Bermejo, Begoña ^b   Zamora, Esther ^e   García Saenz, Jose Angel ^g   Simon, Sonia Pernas ^h   Carrasco, Eva ^o   Escudero, María José ^o   Campo, Ruth ^o   Colomer, Ramón ^p   Blasco, Maria A ^a   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Hospital de Monteprincipe   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ MD ANDERSON CANCER CENTER   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^l HOSPITAL ARNAU DE VILANOVA   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^o GEICAM   (Spain)

^p HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

Breast cancer; Critically short telomeres; Telomere length; Toxicity; Weekly paclitaxel

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NINTEDANIB; PACLITAXEL; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MYALGIA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TELOMERE LENGTH; TELOMERE SHORTENING; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; ADVERSE EVENT; BREAST TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; TELOMERE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLES; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; TELOMERE; TELOMERE SHORTENING;

EID: 85016390733     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15592     Document Type: Article

References (41)

1. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008; 26:1642-1649.
2. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Jr., Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358:1663-1671.
3. Blasco MA. Telomere length, stem cells and aging. Nature chemical biology. 2007; 3:640-649.
4. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet. 2012; 13:693-704.
5. Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev. 2016; 43:19-26.
6. Singh JC, Lichtman SM. Effect of age on drug metabolism in women with breast cancer. Expert Opin Drug Metab Toxicol. 2015; 11:757-766.
7. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153:1194-1217.
8. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008; 8:450-458.
9. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007; 130:223-233.
10. Garg MB, Lincz LF, Adler K, Scorgie FE, Ackland SP, Sakoff JA. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis. Br J Cancer. 2012; 107:1525-1533.
11. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscleinvasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014; 32:1895-1901.
12. Vera E, Blasco MA. Beyond average: potential for measurement of short telomeres. Aging (Albany NY). 2012; 4:379-392. doi: 10.18632/aging.100462.
13. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 2001; 107:67-77.
14. Canela A, Vera E, Klatt P, Blasco MA. High-throughput telomere length quantification by FISH and its application to human population studies. Proc Natl Acad Sci U S A. 2007; 104:5300-5305.
15. Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, Sahin E, Kost-Alimova M, Protopopov A, Cadinanos J, Horner JW, Maratos-Flier E, Depinho RA. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature. 2011; 469:102-106.
16. Bar C, Povedano JM, Serrano R, Benitez-Buelga C, Popkes M, Formentini I, Bobadilla M, Bosch F, Blasco MA. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. Blood. 2016; 127:1770-1779.
17. Garcia-Beccaria M, Martinez P, Mendez-Pertuz M, Martinez S, Blanco-Aparicio C, Canamero M, Mulero F, Ambrogio C, Flores JM, Megias D, Barbacid M, Pastor J, Blasco MA. Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage. EMBO Mol Med. 2015; 7:930-949.
18. Townsley DM, Dumitriu B, Liu D, Biancotto A, Weinstein B, Chen C, Hardy N, Mihalek AD, Lingala S, Kim YJ, Yao J, Jones E, Gochuico BR, et al. Danazol Treatment for Telomere Diseases. N Engl J Med. 2016; 374:1922-1931.
19. Frederiks CN, Lam SW, Guchelaar HJ, Boven E. Genetic polymorphisms and paclitaxel-or docetaxel-induced toxicities: A systematic review. Cancer Treat Rev. 2015; 41:935-950.
20. Quintela-Fandino M, Lluch A, Manso LM, Calvo I, Cortes J, Garcia-Saenz JA, Gil JM, Martinez-Janez N, Gonzalez-Martin A, Adrover E, De Andres R, Vinas G, Llombart Cussac A, et al. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial. Clin Cancer Res. 2016.
21. McIlrath J, Bouffler SD, Samper E, Cuthbert A, Wojcik A, Szumiel I, Bryant PE, Riches AC, Thompson A, Blasco MA, Newbold RF, Slijepcevic P. Telomere length abnormalities in mammalian radiosensitive cells. Cancer Res. 2001; 61:912-915.
22. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15:143-155.
23. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25:4414-4422.
24. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016; 34:611-635.
25. Freedman RA. Treatment of Breast Cancer in the Elderly. Curr Oncol Rep. 2015; 17:51.
26. Cui Y, Cai Q, Qu S, Chow WH, Wen W, Xiang YB, Wu J, Rothman N, Yang G, Shu XO, Gao YT, Zheng W. Association of leukocyte telomere length with colorectal cancer risk: nested case-control findings from the Shanghai Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2012; 21:1807-1813.
27. McGrath M, Wong JY, Michaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007; 16:815-819.
28. Qu S, Wen W, Shu XO, Chow WH, Xiang YB, Wu J, Ji BT, Rothman N, Yang G, Cai Q, Gao YT, Zheng W. Association of leukocyte telomere length with breast cancer risk: nested case-control findings from the Shanghai Women's Health Study. Am J Epidemiol. 2013; 177:617-624.
29. Shen J, Gammon MD, Terry MB, Wang Q, Bradshaw P, Teitelbaum SL, Neugut AI, Santella RM. Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer. 2009; 124:1637-1643.
30. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003; 95:1211-1218.
31. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ. A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009; 18:1152-1156.
32. Kim S, Sandler DP, Carswell G, De Roo LA, Parks CG, Cawthon R, Weinberg CR, Taylor JA. Telomere length in peripheral blood and breast cancer risk in a prospective case-cohort analysis: results from the Sister Study. Cancer Causes Control. 2011; 22:1061-1066.
33. Zheng YL, Ambrosone C, Byrne C, Davis W, Nesline M, McCann SE. Telomere length in blood cells and breast cancer risk: investigations in two case-control studies. Breast Cancer Res Treat. 2010; 120:769-775.
34. Bodelon C, Heaphy CM, Meeker AK, Geller B, Vacek PM, Weaver DL, Chicoine RE, Shepherd JA, Mahmoudzadeh AP, Patel DA, Brinton LA, Sherman ME, Gierach GL. Leukocyte telomere length and its association with mammographic density and proliferative diagnosis among women undergoing diagnostic image-guided breast biopsy. BMC Cancer. 2015; 15:823.
35. Svenson U, Nordfjall K, Stegmayr B, Manjer J, Nilsson P, Tavelin B, Henriksson R, Lenner P, Roos G. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res. 2008; 68:3618-3623.
36. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 2002; 21:619-626.
37. Yeh JK, Wang CY. Telomeres and Telomerase in Cardiovascular Diseases. Genes (Basel). 2016; 7.
38. Ishikawa N, Nakamura K, Izumiyama-Shimomura N, Aida J, Matsuda Y, Arai T, Takubo K. Changes of telomere status with aging: An update. Geriatr Gerontol Int. 2016; 16:30-42.
39. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, Young NS. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009; 114:2236-2243.
40. Bar C, Huber N, Beier F, Blasco MA. Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres. Haematologica. 2015; 100:1267-1274.
41. Lee DC, Im JA, Kim JH, Lee HR, Shim JY. Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med J. 2005; 46:471-479.